Metcela, a Kanagawa, Japan-based clinical-stage biotechnology company developing first-in-class autologous cell therapies targeting serious cardiovascular diseases, raised $14M in Series C funding.
The round was led by CYBERDYNE Inc. and CEJ Fund, with participation from Japan Lifeline Co., Ltd., Sony Innovation Fund and Reazon Holdings, Inc.
The company intends to use the funds to prepare for commercialization through the establishment of manufacturing infrastructure, strengthen new pipeline development capabilities, and reinforce R&D structure by expanding research facilities.
Established in 2016, Metcela is a clinical-stage biotechnology startup pioneering the research and development of fibroblast and stem cell-based therapy for chronic diseases that currently have limited therapeutic options. The company is advancing MTC001, a combination product of autologous cardiac cells (VCAM-1-positive Cardiac Fibroblast, VCF) and a novel catheter delivery system targeting chronic heart failure patients.
FinSMEs
05/07/2022